Cancer cachexia research hub

C3651003 A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)

This study is testing a new medicine called ponsegromab for people with cancer who are also losing weight and muscle (cancer cachexia). It's looking at how well the medicine helps them gain weight and how safe it is over 12 weeks.